These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND HER1, YOR227W AND Treatment
26 results:

  • 1. Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in colorectal cancer.
    Rau A; Janssen N; Kühl L; Sell T; Kalmykova S; Mürdter TE; Dahlke MH; Sers C; Morkel M; Schwab M; Kontermann RE; Olayioye MA
    Mol Cancer Ther; 2022 May; 21(5):799-809. PubMed ID: 35247930
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
    Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
    Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Exploration of a F(ab')
    Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
    Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced colorectal cancer.
    Seligmann JF; Hatch AJ; Richman SD; Elliott F; Jacobs B; Brown S; Hurwitz H; Barrett JH; Quirke P; Nixon AB; Seymour MT
    JAMA Oncol; 2018 Apr; 4(4):564-568. PubMed ID: 29075780
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Neratinib: First Global Approval.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1695-1704. PubMed ID: 28884417
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The prospect of patritumab for treating non-small cell lung cancer.
    Horinouchi H
    Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Epidermal growth factor receptor inhibitors: coming of age.
    Mahipal A; Kothari N; Gupta S
    Cancer Control; 2014 Jan; 21(1):74-9. PubMed ID: 24357745
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
    Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
    J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for her1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. 100% human monoclonal antibodies in oncology: hype or breakthrough?
    Benay S; Fanciullino R; Mercier C; Iliadis A; Ciccolini J; Lacarelle B
    Curr Top Med Chem; 2012; 12(15):1643-8. PubMed ID: 22978333
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
    Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
    J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer.
    de Gramont A; de Gramont A; Chibaudel B; Bachet JB; Larsen AK; Tournigand C; Louvet C; André T;
    Semin Oncol; 2011 Aug; 38(4):521-32. PubMed ID: 21810511
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Preparation, biological evaluation, and pharmacokinetics of the human anti-her1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    J Nucl Med; 2010 Jun; 51(6):942-50. PubMed ID: 20484421
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. PET imaging of her1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
    Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mechanisms of resistance to HER family targeting antibodies.
    Kruser TJ; Wheeler DL
    Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
    Pohl M; Stricker I; Schoeneck A; Schulmann K; Klein-Scory S; Schwarte-Waldhoff I; Hasmann M; Tannapfel A; Schmiegel W; Reinacher-Schick A
    J Cancer Res Clin Oncol; 2009 Oct; 135(10):1377-86. PubMed ID: 19340455
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
    Bianchini D; Jayanth A; Chua YJ; Cunningham D
    Clin Colorectal Cancer; 2008 Jan; 7(1):33-43. PubMed ID: 18279575
    [TBL] [Abstract] [Full Text] [Related]  

    [Next]

    of 2.